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http://dx.doi.org/1diabetes mellitus (DM) compared with placebo and that this relation is dose dependent. The
aim of this study was to perform a comprehensive network meta-analysis of randomized
controlled trials (RCTs) investigating the impact of different types and doses of statins on
new-onset DM. RCTs comparing different types and doses of statins with placebo were
searched for using the MEDLINE, Embase, and Cochrane databases. A search of RCTs
pertinent to this meta-analysis covering the period from November 1994 to October 2012
was conducted by 2 independent investigators using the MEDLINE, Cochrane, Google
Scholar, and Embase databases as well as abstracts and presentations from major cardio-
vascular meetings. Seventeen RCTs reporting the incidence of new-onset DM during statin
treatment and including a total of 113,394 patients were identified. The RCTs compared
either a statin versus placebo or high-dose versus moderate-dose statin therapy. Among
different statins, pravastatin 40 mg/day was associated with the lowest risk for new-onset
DM compared with placebo (odds ratio 1.07, 95% credible interval 0.86 to 1.30).
Conversely, rosuvastatin 20 mg/day was numerically associated with 25% increased risk for
DM compared with placebo (odds ratio 1.25, 95% credible interval 0.82 to 1.90). The impact
on DM appeared to be intermediate with atorvastatin 80 mg/day compared with placebo
(odds ratio 1.15, 95% credible interval 0.90 to 1.50). These findings were replicated at
moderate doses. In conclusion, different types and doses of statins show different potential
to increase the incidence of DM.  2013 Elsevier Inc. All rights reserved. (Am J Cardiol
2013;111:1123e1130)Although generally well tolerated, statins, compared with
placebo, have been associated with a higher incidence of
new-onset diabetes mellitus (DM) in several experimental
studies and a meta-analysis of 13 randomized controlled
trials (RCTs).1,2 Another meta-analysis of 5 studies showed
a dose-dependent effect of statins on the incidence of DM.3
On the basis of these findings, the US Food and Drug
Administration has recently added information to statin
labels regarding the impact of these agents on DM.4 The
constellation of statins is wide, with differences concerning
active compounds, associated effects, and therapeutic doses.
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0.1016/j.amjcard.2012.12.037therapeutic dilemmas regarding which type and dose of
statin may minimize the risk for developing DM. To date,
appropriately powered head-to-head comparisons among
statins with regard to the DM end point are lacking. Given
the perceived need to understand the specific risk for
developing DM associated with one statin compared with
another and to relate that to the administered dose of the
drug, a network meta-analysis is timely and warranted.
Accordingly, we performed a comprehensive network meta-
analysis of RCTs investigating the impact of different types
and doses of statins on new-onset DM.
Methods
Established methods were used in compliance with the
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses statement for reporting systematic reviews
and meta-analyses in health care interventions.5 A search of
pertinent RCTs conducted from November 1994 to October
2012 was performed by 2 independent investigators
covering the MEDLINE, Cochrane, Google Scholar, and
Embase databases as well as abstracts and presentations
from major cardiovascular meetings, using the search string
“statins AND/OR diabetes.” The internal validity of the
RCTs was assessed by 2 independent reviewers.
Citations were screened at the title and abstract level and
retrieved as full reports. Inclusion criteria were (1) studies inwww.ajconline.org
Figure 1. Flow diagram of the network meta-analysis.
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treated with high-dose statins versus placebo or with high-
versus moderate-dose statins connected in a network with
a third comparison (placebo or statin) and reporting the
incidence rates of new-onset DM in both arms. To be
consistent with other large meta-analyses and to provide
robust estimates, we excluded trials with follow-up 1 year
and including <1,000 patients.
A network meta-analysis was planned with respect to
new-onset DM as an end point to compare (1) high-dose
statins versus placebo and different high doses of statins, 2)
moderate-dose statins versus placebo and different moderate
doses of statins, and (3) high-dose versus moderate-dose
statins. This research tool remains a well-established method
capable of comparing different treatments using a common
reference treatment while maintaining the randomization
design and integrating data from direct and indirect
comparisons.6,7
New-onset DM was defined as any adverse event report
of DM, or starting glucose-lowering medication, or a fasting
plasma glucose level 7 mmol/L (either 1 or 2 values,
depending on the frequency of measurement in the trial).
Dichotomous outcome variables were compared using odds
ratios (ORs) and 95% credible intervals (CIs) by means of
network meta-analysis using a Bayesian hierarchical
random-effects model. Analysis was based on non-
informative prior findings for effect sizes and precision.
Convergence and lack of autocorrelation were checked and
confirmed after 10,000 iterations. The final summary statis-
tics were based on a further 100,000 iterations, after dis-
carding the initial 10,000-iteration burn-in. Sensitivity
analysis was conducted by repeating the main computations
using a fixed-effect method. Pairwise contrasts were
examined, and heterogeneity was assessed using the I2
statistic, with values <25%, 25% and 50%, and >50%,
respectively, representing mild, moderate, and severeheterogeneity. Inconsistency between direct and indirect
evidence sources was assessed by inspection of the model fit
and by comparing the results of the pairwise meta-analyses
with the estimates from the network meta-analysis. We
computed the probability that each statin agent was the best
treatment in terms of inducing less DM. The ranking of the
competing drugs was assessed with the median of the
posterior distribution for the rank of each drug; cumulative
ranking probabilities curves for competing statin treatments
were built. The surface under the cumulative ranking curve
(SUCRA) was derived by using the posterior probabilities
for each treatment to be among the n best options; SUCRA
would take a value of 1 when the treatment is certain to be
the best and of 0 when the treatment is certain to be the
worst. A Bayesian random-effects meta-regression was per-
formed to formally explore whether the effect on DM is
related to the power of statins to reduce cholesterol or rather
to a molecule-dependent mechanism. Additionally, the
potential effect on the results of different body mass indexes
(BMIs) across the studies as a proxy for different cardio-
vascular risk profiles was investigated; specifically, in the
meta-regression analysis, the Bayesian OR for DM of each
statin versus placebo was regressed against the percentage of
low-density lipoprotein (LDL) cholesterol reduction using
BMI as a covariate. The goodness of fit of the model to the
data was assessed using the residual deviance.
Results
The flow diagram of the study is shown in Figure 1.
Seventeen RCTs8e24 fulfilling the eligibility criteria and
comprising a total of 113,394 patients were eventually
included for data abstraction. Table 1 lists the main char-
acteristics of the included studies. Fourteen RCTs compared
a statin with placebo, and 3 studies compared high- with
moderate-dose statin therapy. The high daily doses of statins
Table 1
Main clinical characteristics of the included randomized controlled trials

















no history of CAD
Double-blind Atorvastatin 10 mg vs placebo 2,532 (24.6%) 7,773 (75.4%) 3.3*† 154 (3.9%) vs 134 (3.5%) 28.6† 63.0† 34.8% at
12 mosz
HPS9 2003 History of CVD Double-blind Simvastatin 40 mg vs placebo 5,963 (29.0%) 14,573 (71.0%) 5.0 335 (4.6%) vs 293 (4.0%) 27.2 65.0 29.4% average
in trial
JUPITER10 2008 No CVD Double-blind Rosuvastatin 20 mg vs placebo 0 (0%) 17,802 (100.0%) 1.9* 270 (3.0%) vs 216 (2.4%) 28.4* 66.0* 50.0% at 12 mos
WOSCOPS11 2001 No previous MI,
elevated cholesterol
Double-blind Pravastatin 40 mg vs placebo 621 (9.4%) 5,974 (90.6%) 4.8 75 (2.5%) vs 93 (3.1%) 25.9 55.0 23.7% at 12 mos
LIPID12x 2003 MI or UA in
previous 3 yrs




CORONA13 2007 Systolic CHF Double-blind Rosuvastatin 20 mg vs placebo 1,477 (29.5%) 3,534 (70.5%) 2.7*† 100 (5.6%) vs 88 (5.0%) 27.0z 73.0† 45.1% at 3 mos)z
PROSPER14 2002 Elderly patients with
CVD or at high risk
Double-blind Pravastatin 40 mg vs placebo 781 (13.5%) 5,023 (86.5%) 3.2 165 (6.6%) vs 127 (5.1%) 26.5 76.0 30.7% at 12 mos
MEGA15 2006 No CVD, elevated
cholesterol
Open trial Pravastatin 10e20 mg vs
no treatment
1,746 (22.3%) 6,086 (77.7%) 5.3 172 (5.7%) vs 164 (5.3%) 23.8 58.3 17.1% at 12 mos
AFCAPS/
TexCAPS16
1998 No CVD Double-blind Lovastatin 20e40 mg vs placebo 394 (6.0%) 6,605 (94.0%) 5.2† 72 (2.3%) vs 74 (2.4%) 27.0† 58.0† 26.7% at 12 mos
4S17 1994 Previous MI or angina Double-blind Simvastatin 20e40 mg vs placebo 202 (4.5%) 4,242 (95.5%) 5.4* 198 (9.4%) vs 193 (9.1%) 25.9 58.6 36.7% at 12 mos
ALLHAT-
LLT18
2002 CAD or CAD risk
factors
Open trial Pravastatin 40 mg vs no treatment 4,268 (41.2%) 6,087 (58.8%) 4.8† 238 (7.9%) vs 212 (6.9%) 29.0 66.4 18.1% at 24 mos
GISSI-HF19 2008 CHF Double-blind Rosuvastatin 10 mg vs placebo 1,196 (26.1%) 3,378 (73.9%) 3.9* 225 (13.6%) vs 215 (12.5%) 26.7 67.0 34.9% at 12 mos
GISSI
Prevenzione20
2000 MI within past 6 mos Open trial Pravastatin 20 mg vs no treatment 811 (19.0%) 3,460 (81.0%) 2.0* 96 (5.5%) vs 105 (6.1%) 26.3 59.3 11.5% at 12 mos
PROVE-
ITeTIMI 2221
2004 Recent ACS Double-blind Atorvastatin 80 mg vs
pravastatin 40 mg
767 (18.4%) 3,395 (81.6%) 2.0 101 (5.9%) vs 99 (5.9%) 29 58 22%
TNT22 2005 Stable CAD Double-blind Atorvastatin 80 mg vs
atorvastatin 10 mg
2,406 (24.1%) 7,595 (75.9%) 5.0 418 (11.0%) vs 358 (9.4%) 28 61 22%
IDEAL23 2005 Previous MI Double-blind Atorvastatin 80 mg vs
simvastatin 20e40 mgz
1,427 (16.0%) 7,461 (84.0%) 4.8* 240 (6.4%) vs 209 (5.6%) 27 62 16%
SPARCL24 2006 Previous stroke or TIA Double-blind Atorvastatin 80 mg vs placebo 794 (16.8%) 3,937 (83.2%) 4.9 166 (8.7%) vs 115 (6.0%) 27.15 62.5 NA
ACS ¼ acute coronary syndrome; AFCAPS/TexCAPS ¼ Air Force/Texas Coronary Atherosclerosis Prevention Study; ALLHAT-LLT ¼ Antihypertensive and Lipid-Lowering Treatment to Prevent Heart
Attack TrialeLipid-Lowering Trial; ASCOT-LLA ¼ Anglo-Scandinavian Cardiac Outcomes TrialeLipid Lowering Arm; CAD ¼ coronary artery disease; CHF ¼ chronic heart failure; CORONA ¼ Controlled
Rosuvastatin Multinational Trial in Heart Failure; CV ¼ cardiovascular; CVD ¼ cardiovascular disease; 4S ¼ Scandinavian Simvastatin Survival Study; GISSI ¼ Gruppo Italiano per lo Studio Della
Sopravvivenza Nell’Infarto Miocardico; GISSI-HF ¼ Gruppo Italiano per lo Studio Della Sopravvivenza Nell’Infarto MiocardicoeHeart Failure; HPS ¼ Heart Protection Study; IDEAL ¼ Incremental Decrease
in End Points Through Aggressive Lipid Lowering; JUPITER ¼ Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin; LIPID ¼ Long-Term Intervention With
Pravastatin in Ischemic Disease; MEGA ¼ Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese; MI ¼ myocardial infarction; NA ¼ not available; PROSPER ¼ Prospective
Study of Pravastatin in the Elderly at Risk; PROVE-ITeTIMI 22 ¼ Pravastatin or Atorvastatin Evaluation and Infection TherapyeThrombolysis In Myocardial Infarction 22; SPARCL ¼ Stroke Prevention by
Aggressive Reduction in Cholesterol Levels; TIA ¼ transient ischemic attack; TNT ¼ Treating to New Targets; UA ¼ unstable angina; WOSCOPS ¼ West of Scotland Coronary Prevention Study.
* Median.
† Data from total cohort including patients with DM at baseline.
z If, at 24 weeks, plasma total cholesterol level was>190 mg/dl (5.0 mmol/L), the dose of simvastatin could be increased to 40 mg/day. The dose of atorvastatin could be decreased to 40 mg/day for adverse events.















Figure 2. Evidence network of statins included in the meta-analysis. The
nodes are the different treatments, and the edges represent trials comparing
2 treatments (statin or placebo). The widths of the lines are proportional to
the number of trials comparing each pair of treatments. There is no line
when there is no direct randomized comparison.
1126 The American Journal of Cardiology (www.ajconline.org)used in the RCTs were atorvastatin 80 mg, lovastatin 20 to
40 mg, pravastatin 40 mg, rosuvastatin 20 mg, and sim-
vastatin 40 mg. The moderate doses were atorvastatin
10 mg, pravastatin 10 to 20 mg, and rosuvastatin 10 mg, all
administered once daily. The included statins were con-
nected in a network, as shown in Figure 2. The final model
reached a posterior mean residual deviance of 34.46 (the
number of data points was 34), indicating a very good fit of
the model. The estimated effects from the pairwise meta-
analyses were comparable with the results of the network
meta-analysis, suggesting no evidence of inconsistency.
A total of 9 studies including 64,137 patients contributed
to the analysis of new-onset DM in patients treated with
high-dose statins, compared with a placebo control group. In
the overall cohort, there was a total of 4,610 cases of new-
onset DM: 7.28% (2,335 of 32,070) in the high-dose statin
group and 7.09% (2,275 of 32,067) in the control group. As
shown in Figure 3, treatment with rosuvastatin 20 mg/day,
compared with placebo, was associated with a numeric 25%
relative increase in the risk for developing new-onset DM.
The impact on the risk for DM with atorvastatin 80 mg/day
was less evident. Conversely, therapy with pravastatin
40 mg/day was associated with the lowest risk for DM,
almost comparable with placebo treatment. The results for
simvastatin 40 mg/day were substantially comparable with
those for rosuvastatin 20 mg/day. Pravastatin 40 mg/day was
associated with a consistent relative risk reduction of new-
onset DM (16%) compared with rosuvastatin 20 mg/day,
and atorvastatin 80 mg/day resulted in an approximately 8%
relative risk reduction for new-onset DM compared with
high-dose rosuvastatin.
Eleven studies including 63,558 patients reported rates of
DM in patients treated with either moderate doses of statins
or placebo. In patients treated with moderate-dose statins,
there were 2,601 cases of DM among 31,764 patients
(8.18%) compared with 2,527 cases among 31,794 patients
(7.95%) in the control group. Figure 3 shows that even
moderate-dose rosuvastatin therapy still created the highest
risk for DM. Treatment with atorvastatin 10 mg/day wasalmost comparable with placebo, whereas pravastatin
10 mg/day was associated with a numerically lower risk for
DM compared with placebo. The results also show
a numerically lower risk associated with pravastatin treat-
ment compared with rosuvastatin. At moderate doses, the
risks for DM with atorvastatin and rosuvastatin were
comparable.
Figure 3 presents the effect on new-onset DM of high
versus moderate doses of statins. The risk for DM was
generally increased with higher dose statin regimens. With
rosuvastatin 20 mg/day, a 12% increase in the relative risk for
DM was observed, compared with rosuvastatin 10 mg/day.
High-dose pravastatin was associated with a slightly
increased relative risk (7%) compared with low-dose pra-
vastatin. The risk for DM did not appear to increase
comparing lower with higher dose atorvastatin.
Figure 4 summarizes the likelihood of being the best
high-dose statin treatment in terms of inducing less DM
compared with placebo. Pravastatin at high doses was found
to have the highest probability to be in the top ranks for the
best treatment, presenting a relative SUCRA of 0.53.
Atorvastatin at high doses ranked second, with a SUCRA of
0.37. The lowest 2 positions belonged to high-dose rosu-
vastatin and simvastatin, associated with SUCRAs of 0.30
and 0.29, respectively.
Figure 5 summarizes the probabilities of noninferiority to
placebo for various threshold values, expressed as ORs, for
statin therapy compared with placebo.
As shown, it is possible to be 60% certain that
compared with placebo, pravastatin 40 mg/day is <1.1-fold
worse. Conversely, with rosuvastatin 20 mg/day, this
probability is reduced to approximately 20%.
By meta-regression, the ORs and 95% CIs for different
types and doses of statins compared with placebo adjusted
for the covariate LDL reduction were comparable with those
in the overall analyses without the covariate (Table 2); the
b coefficient in the meta-regression analysis with LDL
reduction as a covariate were very low, therefore excluding
a relation between the OR for DM with different statins
compared with placebo and the percentage of LDL reduc-
tion with the different statins (Table 2). The meta-regression
model fitted the data very well, with a posterior mean
residual deviance of 36.3 (compared with 34 data points).
The b coefficient in the meta-regression with BMI vari-
ations treated as a covariate was 0.008795, with a 95% CI
of 0.0248 to 0.00675, which is narrow and includes 0,
suggesting that mean BMI does not explain variations in
treatment effects among studies and across treatment
comparisons. Sensitivity analysis on the basis of fixed-effect
methods confirmed the results found with the random-
effects meta-analysis, as listed in Table 3.
Discussion
The present study is the largest and most comprehensive
study thus far comparing rates of new-onset DM among
different types and doses of statins. The main findings
derived from a population of 113,394 patients were as
follows: (1) there was a gradient for the risk for new-onset
DM across different types and doses of statins, (2) pravas-
tatin therapy was numerically associated with the lowest rate
Figure 3. Pooled ORs and 95% CIs determined by the network meta-analysis for (A) high doses of a statin compared with placebo or with another statin, (B)
moderate doses of a statin compared with placebo or with another statin, and (C) moderate doses compared with high doses of a statin. Atorv ¼ atorvastatin;
Prav ¼ pravastatin; Rosuv ¼ rosuvastatin; Simv ¼ simvastatin.
Figure 4. Ranking probability plots for competing statins drawn by extrapolating at the middle of each interval of the step function. On the horizontal axis is the
possible rank of each treatment (from the first best rank to the worse according to outcome). On the vertical axis is the probability for each treatment to have that
rank with respect to the odds of new-onset DM.
Preventive Cardiology/Statins and Diabetes: Network Meta-Analysis 1127of new-onset DM compared with other statins, whereas
treatment with rosuvastatin was associated with the highest
numeric incidence of DM, (3) the cumulative probabilitiesindicated that high-dose pravastatin had the highest proba-
bility to be the safest treatment in terms of new-onset DM,
with rosuvastatin and simvastatin performing least well in
Figure 5. Probabilities to be no worse than placebo for (A) high doses of statins and (B) moderate doses of statins regarding the incidence of new-onset DM by
a certain threshold t value (on the horizontal axis) measured on an OR scale.
Table 2
Odds ratios and 95% credible intervals of diabetes among different statins
adjusted for percentage of low-density lipoprotein cholesterol reduction as
covariate
Comparison OR 95% CI
Atorvastatin 10 mg vs Placebo 1.04 0.74e1.48
Pravastatin 20 mg vs placebo 0.99 0.68e1.41
Rosuvastatin 10 mg vs placebo 1.10 0.78e1.58
Simvastatin 40 mg vs placebo 1.21 0.93e1.57
Atorvastatin 80 mg vs placebo 1.15 0.90e1.51
Lovastatin 40 mg vs placebo 0.97 0.58e1.61
Pravastatin 40 mg vs placebo 1.06 0.85e1.30
Rosuvastatin 20 mg vs placebo 1.25 0.75e2.01
Beta coefficient¼ 0.0003 (95%CI0.01 to 0.01); residual deviance¼ 36.3.
1128 The American Journal of Cardiology (www.ajconline.org)this ranking, (4) compared with placebo, high-dose pra-
vastatin provided the most robust safety profile compared
with the other high-dose statins, with a 60% margin of
certainty not to be 1.1-fold worse than placebo, (5) these
findings were confirmed with moderate doses of statins, and
(6) for each statin, increased doses carried a numerically
higher risk for new-onset DM compared with moderate
doses.
Numerous RCTs8e24 have shown consistent benefits
with statins in reduction of mortality and cardiovascular
events, especially in the diabetic population, in which
cardiovascular disease is the leading cause of mortality. In
contrast, a recent meta-analysis revealed that statin therapy
is associated with an increased risk for developing DM.4
Moreover, a newly published meta-analysis showed a dose-
dependent effect, with a 12% higher relative risk for
developing DM on intensive-dose statin therapy compared
with moderate-dose therapy.5 Potential molecular explana-
tions for the increased risk for DM observed with statin
therapy include modifications in insulin signaling in
peripheral tissues, exacerbating insulin resistance, and/or
interaction with pancreatic b-cell function, impairing insulin
secretion.25 Further suggested mechanisms influencing the
risk for DM with statins are the power of particular statins to
reduce cholesterol concentration and the fact that patientsare sometimes aware of their treatment allocation in trials26;
this bias may lead those with substantially reduced LDL
cholesterol to become complacent and assume poorer life-
styles, gain weight, and ultimately develop DM. However,
the present study clearly showed by meta-regression that the
risk for developing DM was not influenced by the different
abilities of statins to reduce cholesterol; on the basis of this
additional datum, this meta-analysis prompts the experi-
mental investigation of molecule-dependent mechanisms
responsible for DM onset. Notably, our findings are
consistent with an experimental study recently performed by
Koh et al,27 who found that rosuvastatin is more potent and
less hydrophilic than pravastatin and is associated with
adverse metabolic effects, including increases in insulin
resistance and glycosylated hemoglobin; conversely, pra-
vastatin proved to be safe by decreasing these 2 parameters.
In agreement with our findings, the Irish Health Services
Executive Primary Care Reimbursement Services national
pharmacy claims database28 demonstrated that rosuvastatin
was associated with the highest increase in new-onset DM
compared with other statins.
A recent meta-analysis showed a significant benefit with
statins in patients with a 5-year risk for major vascular
events <10%, demonstrating that this benefit exceeds any
hazard of statin therapy, including DM.29 Understanding the
risk for DM across the spectrum of different statins is
important to balance the risks and benefits when adminis-
tering specific statins. In the present report, a numeric 25%
increase in the relative risk for DM was found with high
doses of rosuvastatin compared with placebo, whereas high-
dose pravastatin only moderately enhanced this risk by 7%;
this datum derived from the present large scale network
meta-analysis is comparable with the reported 27% increase
in the relative risk for DM in rosuvastatin-treated patients
compared with placebo-treated patients detected in the
Justification for the Use of Statins in Primary Prevention:
An Intervention Trial Evaluating Rosuvastatin (JUPITER)
trial.10 The estimated risk for new-onset DM associated with
rosuvastatin found in our meta-analysis is almost twice as
high as the overall risk with statin treatment reported in the
meta-analysis by Sattar et al.2
Table 3
Odds ratios and 95% credible intervals of diabetes among different statin types and doses
Comparison High-Dose Statin Moderate-Dose Statin
Random Effects Fixed Effect Random Effects Fixed Effect
Atorvastatin vs placebo 1.15 (0.90e1.50) 1.13 (1.00e1.27) 1.04 (0.75e1.46) 1.00 (0.85e1.17)
Lovastatin vs placebo 0.98 (0.59e1.61) 0.98 (0.71e1.36) NA NA
Pravastatin vs placebo 1.07 (0.86e1.30) 1.07 (0.95e1.20) 0.90 (0.71e1.35) 1.00 (0.78e1.27)
Rosuvastatin vs placebo 1.25 (0.82e1.90) 1.25 (1.0e1.54) 1.11 (0.81e1.52) 1.10 (0.88e1.4)
Simvastatin vs placebo 1.21 (0.94e1.56) 1.27 (1.13e1.41) NA NA
Atorvastatin vs pravastatin 1.08 (0.82e1.47) 1.04 (0.90e1.21) 1.16 (0.78e1.77) 1.18 (0.90e1.55)
Atorvastatin vs rosuvastatin 0.92 (0.57e1.51) 0.90 (0.71e1.12) 0.93 (0.59e1.48) 0.90 (0.72e1.13)
Atorvastatin vs simvastatin 0.94 (0.72e1.28) 0.88 (0.80e0.97) NA NA
Pravastatin vs rosuvastatin 0.84 (0.53e1.34) 0.85 (0.67e1.06) 0.87 (0.58e1.30) 0.90 (0.71e1.15)
Pravastatin vs simvastatin 0.87 (0.63e1.19) 0.84 (0.73e0.99) NA NA
Rosuvastatin vs simvastatin 1.03 (0.63e1.68) 1.0 (0.81e1.23) NA NA
Estimates derived from fixed-effect and random-effects models are reported.
Preventive Cardiology/Statins and Diabetes: Network Meta-Analysis 1129The findings of this large network meta-analysis are the
first to provide information on the specific risk for DM
associated with different types and doses of statins. Because
of the limited available direct evidence, large 95% CIs were
found around the overall estimates; in contrast, the stability of
the results in several probability and ranking analyses make
the overall conclusions justified. If the findings of this
network meta-analysis were confirmed in powered head-to-
head comparisons, they would have important implications
for the futuremanagement of millions of individuals receiving
statins worldwide; indeed, a new scenario of statin therapy
could be envisaged in which personalized statin therapymight
emerge as the most effective and safest strategy.
As with any meta-analysis, our study shares the limita-
tions of the original studies. Methods for the diagnosis of
incident DM varied among trials, which is common in such
studies. In the original West of Scotland Coronary Preven-
tion Study (WOSCOPS) trial, the diagnostic criteria for DM
were nonstandard, with a requirement for an increase in
fasting glucose of 2.0 mmol/L during the trial. However,
for the present analysis, standard criteria for the diagnosis of
DM from a reanalysis of WOSCOPS were used.11 These
data were made available in the previously published meta-
analysis by Sattar et al.2Acknowledgment: The present study is a project of
Systematic Investigation and Research on Interventions and
Outcomes (SIRIO)eMEDICINE, an international scientific
group committed to research and innovation in medicine.Disclosures
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